In the LS1034 model, the combination treatment resulted in 4/5 (75%) tumours being negative for cytokeratin and Ki67 staining less than 50%, compared to only 1/6 (16%) in the Ribociclib group. The gene discussed is MKI67; the disease is neoplasm.